Functional Dyspepsia Clinical Trial
— SIBOOfficial title:
Small Intestinal Bacterial Overgrowth: A Prospective Registry
Verified date | February 2022 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The purpose of this study is to investigate the prevalence of small intestinal bacterial overgrowth (SIBO) in patients who will be undergoing an enteroscopy as an outpatient procedure with symptoms of functional dyspepsia. In addition, the investigators would like to identify the types of bacteria that are present in the small intestines in patients with SIBO and compare two different diagnostic tools: microbiologic culture and DNA sequencing of bacteria. The aim is to compare the microbiota between patients with and without the clinical complications of SIBO
Status | Enrolling by invitation |
Enrollment | 200 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | 1.Study Subjects Inclusion Criteria i. All patients who are undergoing small bowel aspiration for suspected SIBO regardless etiology. Exclusion Criteria i. Use of colon cleansing prep in the past 1 month ii. Treatment with antibiotics in the past 30 days (antibiotics are allowable for patients undergoing clinical indicated repeat aspiration to determine bacteria clearance) iii. Use of probiotics in the past 30 days iv. Contraindication for upper endoscopy for any reason v. Prisoners vi. Pregnant vii. Unable to give own informed consent 2 Control Subjects Inclusion Criteria i. Patients who are undergoing double balloon enteroscopy or upper enteroscopy for another medical reason. Exclusion Criteria i. Diagnosis of SIBO ii. Diagnosis of functional dyspepsia iii. Established risk factors for SIBO (ANY of the following) 1. Connective tissue disorder (scleroderma, polymyositis, mixed connective tissue disease, or systemic lupus 2. Resection of ileocecal valve for any reason 3. Chronic intestinal pseudo-obstruction 4. Small bowel blind limb, diverticulum or fistula 5. Surgery with decreased gastric acid exposure for small bowel a. Gastric surgery with vagotomy (Bilroth I, Bilroth II, vagotomy/pyloroplasty) or gastric bypass iv. Use of colon cleansing prep in the past 1 month v. Use of antibiotics in the past 30 days vi. Use of probiotics in the past 30 days vii. Contraindication for upper endoscopy for any reason viii. Prisoners ix. Pregnant x. Unable to give own informed |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Hospital | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | Progenity, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the predictors for SIBO in patients with functional dyspepsia, who do not have the established risk factors for SIBO | In this population, prevalence of potential predictors of SIBO will be compared between subjects with and without a diagnosis of Gram Negative Bacteria SIBO | two years | |
Secondary | A registry of patients undergoing proximal jejunal aspiration for suspected small intestinal bacterial overgrowth | A prospective registry will be created for all subjects who are undergoing jejunal aspirate for clinical indications. Private health information will be excluded from the data registry. Data collected for the registry will include:
Demographics Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index total and subscale scores Presence of functional gastrointestinal disorders Established risk factors of gram negative small intestinal bacterial overgrowth. Established risk factors of upper respiratory tract small intestinal bacterial overgrowth |
Two years | |
Secondary | The demographics, clinical history, and symptoms in patients with and without SIBO | Demographics 2. Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index total and subscale scores 3. Presence of functional gastrointestinal disorders 4. Established risk factors of gram negative small intestinal bacterial overgrowth.
5. Established risk factors of upper respiratory tract small intestinal bacterial overgrowth |
One day | |
Secondary | Characterize the clinical differences between small intestinal bacterial overgrowth by upper respiratory tract bacteria and small intestinal bacterial overgrowth by gram-negative bacilli bacteria | clinical differences between small intestinal bacterial overgrowth by upper respiratory tract bacteria | One day | |
Secondary | Compare the composition between luminal and mucosal bacteria in the proximal small bowel | Compare the results of bacteria species isolated from molecular polymerase chain reaction identification between luminal aspiration samples and mucosa biopsy samples. | One day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04464369 -
Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial
|
Phase 4 | |
Completed |
NCT01671670 -
Acupuncture for Patients With Function Dyspepsia
|
Phase 2/Phase 3 | |
Completed |
NCT00987805 -
Efficacy of Banhasasim-tang on Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00693407 -
Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation
|
N/A | |
Completed |
NCT00761358 -
To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT01240096 -
Mirtazapine Versus Placebo in Functional Dyspepsia
|
Phase 4 | |
Recruiting |
NCT04540549 -
Effects of Exercise on Functional Dyspepsia Based on Rome IV
|
N/A | |
Recruiting |
NCT03652571 -
Nortriptyline for the Treatment of Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Recruiting |
NCT03825692 -
International Clinical Study of Zhizhu Kuanzhong Capsule
|
Phase 4 | |
Not yet recruiting |
NCT04548011 -
Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia
|
N/A | |
Terminated |
NCT02567578 -
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT03007433 -
Assessment of GI Function to a Large Test Meal by Non-invasive Imaging
|
N/A | |
Active, not recruiting |
NCT00990405 -
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00404534 -
Helicobacter Eradication Relief of Dyspeptic Symptoms
|
Phase 3 | |
Completed |
NCT03043625 -
Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia
|
N/A | |
Completed |
NCT03225248 -
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05587127 -
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT01021475 -
Does Visceral Manipulation Works in Treating Functional Dyspepsia?
|
Phase 1 |